Certara, Inc. (NASDAQ:CERT) insider Robert Aspbury sold 19,354 shares of the stock in a transaction that occurred on Monday, June 14th. The shares were sold at an average price of $27.59, for a total transaction of $533,976.86. Following the sale, the insider now directly owns 375,451 shares of the company’s stock, valued at approximately $10,358,693.09. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Certara stock opened at $26.70 on Wednesday. The company has a market cap of $4.08 billion and a PE ratio of -83.44. Certara, Inc. has a 52-week low of $24.36 and a 52-week high of $41.79. The stock’s 50 day simple moving average is $27.82. The company has a debt-to-equity ratio of 0.36, a current ratio of 5.48 and a quick ratio of 5.48.
Certara (NASDAQ:CERT) last issued its earnings results on Thursday, May 6th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.01. The firm had revenue of $66.72 million during the quarter, compared to the consensus estimate of $64.94 million. The company’s quarterly revenue was up 16.1% on a year-over-year basis. Sell-side analysts expect that Certara, Inc. will post 0.2 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of CERT. GSA Capital Partners LLP bought a new position in shares of Certara in the 4th quarter worth $405,000. SG Americas Securities LLC bought a new position in shares of Certara in the 4th quarter worth $391,000. BlackRock Inc. bought a new position in shares of Certara in the 4th quarter worth $35,205,000. Jennison Associates LLC bought a new position in shares of Certara in the 4th quarter worth $2,595,000. Finally, AGF Investments Inc. bought a new position in shares of Certara in the 4th quarter worth $2,529,000. Institutional investors own 28.48% of the company’s stock.
CERT has been the subject of a number of recent analyst reports. Barclays decreased their target price on shares of Certara from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, May 7th. Morgan Stanley decreased their target price on shares of Certara from $35.00 to $33.00 and set an “equal weight” rating for the company in a research report on Monday, March 8th. William Blair reissued an “outperform” rating on shares of Certara in a research report on Friday, March 5th. Finally, Zacks Investment Research cut Certara from a “hold” rating to a “sell” rating in a report on Wednesday, May 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. Certara currently has a consensus rating of “Hold” and an average price target of $35.40.
About Certara
Certara Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development.
Recommended Story: Outstanding Shares and The Effect on Share Price